t
Coiled Therapeutics plc announced its total voting rights on April 1, 2026. The company's total issued share capital consists of 425,856,539 ordinary shares of 1p each, all with voting rights. Coiled Therapeutics plc holds no shares in treasury, resulting in a total of 425,856,539 voting rights.
| Date | 1 Apr 2026 |
| Time | 07:00:04 |
| Category | Capital structure |
| ID | 9296Y |
1 April 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Total Voting Rights
Coiled Therapeutics plc (AIM:COIL), announces, following the Company's recent successful Admission to trading on AIM and for the purpose of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 425,856,539 ordinary shares of 1p each ("Ordinary Shares") with voting rights.
The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 425,856,539. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)
|
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino
|
+44 (0)20 4530 6926
+61 (0)8 9223 2222 |
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000
|
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.
By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.
The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.
For more information, please visit: www.coiledplc.com